JP2012527438A - 正常駆出率心不全の治療 - Google Patents
正常駆出率心不全の治療 Download PDFInfo
- Publication number
- JP2012527438A JP2012527438A JP2012511329A JP2012511329A JP2012527438A JP 2012527438 A JP2012527438 A JP 2012527438A JP 2012511329 A JP2012511329 A JP 2012511329A JP 2012511329 A JP2012511329 A JP 2012511329A JP 2012527438 A JP2012527438 A JP 2012527438A
- Authority
- JP
- Japan
- Prior art keywords
- patients
- exercise
- perhexiline
- heart
- energy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010019280 Heart failures Diseases 0.000 title description 37
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229960000989 perhexiline Drugs 0.000 claims abstract description 45
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 8
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims 2
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 230000002861 ventricular Effects 0.000 description 41
- 230000000747 cardiac effect Effects 0.000 description 37
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 29
- 230000000284 resting effect Effects 0.000 description 25
- 230000003205 diastolic effect Effects 0.000 description 22
- 239000000902 placebo Substances 0.000 description 22
- 229940068196 placebo Drugs 0.000 description 22
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 230000002159 abnormal effect Effects 0.000 description 12
- 230000005856 abnormality Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000002107 myocardial effect Effects 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 11
- 230000008828 contractile function Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000002592 echocardiography Methods 0.000 description 10
- 239000002876 beta blocker Substances 0.000 description 9
- 229940097320 beta blocking agent Drugs 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 238000004611 spectroscopical analysis Methods 0.000 description 9
- 206010007558 Cardiac failure chronic Diseases 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 7
- 200000000007 Arterial disease Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 230000036284 oxygen consumption Effects 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000002057 chronotropic effect Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000007310 pathophysiology Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 229940124549 vasodilator Drugs 0.000 description 5
- 239000003071 vasodilator agent Substances 0.000 description 5
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000005240 left ventricle Anatomy 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000003044 adaptive effect Effects 0.000 description 3
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000009206 nuclear medicine Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 102000008873 Angiotensin II receptor Human genes 0.000 description 2
- 108050000824 Angiotensin II receptor Proteins 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 206010071436 Systolic dysfunction Diseases 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- DDPMGIMJSRUULN-UHFFFAOYSA-N buphedrone Chemical compound CCC(NC)C(=O)C1=CC=CC=C1 DDPMGIMJSRUULN-UHFFFAOYSA-N 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 238000002564 cardiac stress test Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000009613 pulmonary function test Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 1
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- LJCWONGJFPCTTL-ZETCQYMHSA-N L-4-hydroxyphenylglycine Chemical compound OC(=O)[C@@H](N)C1=CC=C(O)C=C1 LJCWONGJFPCTTL-ZETCQYMHSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 238000001358 Pearson's chi-squared test Methods 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000009091 contractile dysfunction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229950010617 oxfenicine Drugs 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013125 spirometry Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000009662 stress testing Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000010967 transthoracic echocardiography Methods 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2009/050539 WO2010133815A1 (en) | 2009-05-20 | 2009-05-20 | Treatment of heart failure with normal ejection fraction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075231A Division JP2015147787A (ja) | 2015-04-01 | 2015-04-01 | 正常駆出率心不全の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012527438A true JP2012527438A (ja) | 2012-11-08 |
| JP2012527438A5 JP2012527438A5 (enExample) | 2014-07-24 |
Family
ID=41213178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511329A Pending JP2012527438A (ja) | 2009-05-20 | 2009-05-20 | 正常駆出率心不全の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8440697B2 (enExample) |
| EP (1) | EP2432470A1 (enExample) |
| JP (1) | JP2012527438A (enExample) |
| CN (1) | CN102573844A (enExample) |
| AU (1) | AU2009346606B2 (enExample) |
| BR (1) | BRPI0924398A2 (enExample) |
| CA (1) | CA2816448A1 (enExample) |
| IL (1) | IL216362A0 (enExample) |
| MX (1) | MX2011012310A (enExample) |
| WO (1) | WO2010133815A1 (enExample) |
| ZA (1) | ZA201109332B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0405381D0 (en) | 2004-03-10 | 2004-04-21 | Univ Wales Medicine | A method and means for treating heart failure |
| WO2010133815A1 (en) | 2009-05-20 | 2010-11-25 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
| GB0908193D0 (en) | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
| US10137093B2 (en) | 2011-08-16 | 2018-11-27 | Cardiora Pty Ltd. | Milrinone controlled-release formulation |
| WO2014036603A1 (en) * | 2012-09-05 | 2014-03-13 | Adelaide Research & Innovation Pty Ltd | Uses of (-)-perhexiline |
| BR112017013015A2 (pt) * | 2014-12-22 | 2018-03-06 | Cardiora Pty Ltd | método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef) |
| MX2019007125A (es) | 2016-12-15 | 2019-09-16 | Baxter Int | Sistema y metodo para monitorizar y determinar parametros de paciente a partir de forma de onda venosa detectada. |
| US11039754B2 (en) | 2018-05-14 | 2021-06-22 | Baxter International Inc. | System and method for monitoring and determining patient parameters from sensed venous waveform |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007528378A (ja) * | 2004-03-10 | 2007-10-11 | ハート メタボリクス リミテッド | 慢性心不全を治療するためのペルヘキシリン |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN380695A0 (en) | 1995-06-23 | 1995-07-20 | Queen Elizabeth Hospital, The | Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions |
| US20030162824A1 (en) | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
| CL2004000366A1 (es) | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
| WO2005097121A1 (en) | 2004-04-06 | 2005-10-20 | Angiogenetics Sweden Ab | Angiogenesis-affecting compounds and methods of use thereof |
| DE602006011363D1 (de) | 2005-12-01 | 2010-02-04 | Hoffmann La Roche | Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer |
| ITRM20060090A1 (it) | 2006-02-22 | 2007-08-23 | Sigma Tau Ind Farmaceuti | Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita |
| WO2010133815A1 (en) | 2009-05-20 | 2010-11-25 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
| GB0723100D0 (en) * | 2007-11-23 | 2008-01-02 | Heart Metabolics Ltd | Treatment of HFnEF |
| GB0908193D0 (en) | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
| US20140019207A1 (en) | 2012-07-11 | 2014-01-16 | Sap Ag | Interactive in-memory based sales forecasting |
| WO2014036603A1 (en) | 2012-09-05 | 2014-03-13 | Adelaide Research & Innovation Pty Ltd | Uses of (-)-perhexiline |
| WO2015131231A1 (en) | 2014-03-03 | 2015-09-11 | Adelaide Research & Innovation Pty Ltd | Methods for using (-)-perhexiline |
-
2009
- 2009-05-20 WO PCT/GB2009/050539 patent/WO2010133815A1/en not_active Ceased
- 2009-05-20 EP EP09785222A patent/EP2432470A1/en not_active Withdrawn
- 2009-05-20 BR BRPI0924398A patent/BRPI0924398A2/pt not_active IP Right Cessation
- 2009-05-20 CA CA2816448A patent/CA2816448A1/en not_active Abandoned
- 2009-05-20 CN CN2009801606783A patent/CN102573844A/zh active Pending
- 2009-05-20 MX MX2011012310A patent/MX2011012310A/es unknown
- 2009-05-20 JP JP2012511329A patent/JP2012527438A/ja active Pending
- 2009-05-20 AU AU2009346606A patent/AU2009346606B2/en not_active Ceased
-
2010
- 2010-05-21 US US12/785,077 patent/US8440697B2/en not_active Expired - Fee Related
-
2011
- 2011-11-14 IL IL216362A patent/IL216362A0/en unknown
- 2011-12-19 ZA ZA2011/09332A patent/ZA201109332B/en unknown
-
2013
- 2013-03-15 US US13/839,313 patent/US9468634B2/en not_active Expired - Fee Related
- 2013-03-15 US US13/838,458 patent/US9457017B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007528378A (ja) * | 2004-03-10 | 2007-10-11 | ハート メタボリクス リミテッド | 慢性心不全を治療するためのペルヘキシリン |
Non-Patent Citations (4)
| Title |
|---|
| CSNC201000308024; 大塚 美里: '心エコ-を用いた心不全の病態解析と重症度判定 Ｅｃｈａｃａｒｄｉｏｇｒａｐｈｉｃ ｅｖａｌｕａｔｉｏｎ ｏｆ ｖｅｎｔｒｉｃｕｌａｒ ｓｙｓｔｏｌ' 医学のあゆみ 第２１６巻、第１号, 2006, 第９９-１０４頁 * |
| JPN5012013363; ＣＯＡＴＳ Ｃ Ｊ: 'ＣＵＲＲＥＮＴ ＭＡＮＡＧＥＭＥＮＴ ＯＦ ＨＹＰＥＲＴＲＯＰＨＩＣ ＣＡＲＤＩＯＭＹＯＰＡＴＨＹ' Ｃｕｒｒｅｎｔ Ｔｒｅａｔｍｅｎｔ Ｏｐｔｉｏｎｓ ｉｎ Ｃａｒｄｉｏｖａｓｃｕｌａｒ Ｍｅｄｉｃｉｎｅ Ｖ１０ Ｎ６, 2008, Ｐ４９６-５０４ * |
| JPN6013059053; Ｋ． Ｙａｍａｍｏｔｏ， ｅｔ． ａｌ．: 'Ｈｅａｒｔ Ｆａｉｌｕｒｅ Ｗｉｔｈ Ｐｒｅｓｅｒｖｅｄ Ｅｊｅｃｔｉｏｎ Ｆｒａｃｔｉｏｎ-Ｗｈａｔ ｉｓ Ｋｎｏｗｎ ａｎｄ Ｕｎｋｎｏｗｎ-' Ｃｉｒｃｕｌａｔｉｏｎ Ｊｏｕｒｎａｌ Ｖｏｌ．７３, 200903, ｐ．４０４-４１０ * |
| JPN6013059055; 大塚 美里: '心エコ-を用いた心不全の病態解析と重症度判定 Ｅｃｈａｃａｒｄｉｏｇｒａｐｈｉｃ ｅｖａｌｕａｔｉｏｎ ｏｆ ｖｅｎｔｒｉｃｕｌａｒ ｓｙｓｔｏｌ' 医学のあゆみ 第２１６巻、第１号, 2006, 第９９-１０４頁 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201109332B (en) | 2012-08-29 |
| AU2009346606B2 (en) | 2016-06-02 |
| US8440697B2 (en) | 2013-05-14 |
| US20130210719A1 (en) | 2013-08-15 |
| EP2432470A1 (en) | 2012-03-28 |
| CA2816448A1 (en) | 2010-11-25 |
| IL216362A0 (en) | 2012-01-31 |
| US9468634B2 (en) | 2016-10-18 |
| US20130210720A1 (en) | 2013-08-15 |
| US20100331364A1 (en) | 2010-12-30 |
| MX2011012310A (es) | 2012-04-11 |
| WO2010133815A1 (en) | 2010-11-25 |
| CN102573844A (zh) | 2012-07-11 |
| AU2009346606A1 (en) | 2012-01-19 |
| US9457017B2 (en) | 2016-10-04 |
| BRPI0924398A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9457017B2 (en) | Treatment of heart failure | |
| AU2010247120B2 (en) | Perhexiline for use in the treatment of hypertrophic cardiomyopathy (HCM) | |
| Spirito et al. | The management of hypertrophic cardiomyopathy | |
| Tsang et al. | Effects of quinapril on left atrial structural remodeling and arterial stiffness | |
| US8697677B2 (en) | Perhexiline for treating chronic heart failure | |
| Li et al. | Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy | |
| Takahashi et al. | Microalbuminuria, cardiovascular autonomic dysfunction, and insulin resistance in patients with type 2 diabetes mellitus | |
| Roubin et al. | Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol. | |
| Takahashi et al. | Hypoadiponectinemia in type 2 diabetes mellitus in men is associated with sympathetic overactivity as evaluated by cardiac 123I-metaiodobenzylguanidine scintigraphy | |
| Nakae et al. | Augmentation index and pulse wave velocity as indicators of cardiovascular stiffness | |
| WO2009066085A1 (en) | Treatment of heart failure with normal ejection fraction | |
| JP2015147787A (ja) | 正常駆出率心不全の治療 | |
| Izawa et al. | Impaired response of left ventricular relaxation to exercise-induced adrenergic stimulation in patients with hypertrophic cardiomyopathy | |
| Bøttcher et al. | Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy | |
| Jansson et al. | More favourable haemodynamic effects from metoprolol than from captopril in patients with dilated cardiomyopathy | |
| Iwashima et al. | Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan | |
| Agostoni et al. | Exercise performance in patients with uncomplicated essential hypertension: effects of nifedipine-induced acute blood pressure reduction | |
| Kitzman et al. | Exercise intolerance in patients with heart failure: role of diastolic dysfunction | |
| van Leeuwen et al. | Comparative effects of diltiazem and lisinopril on left ventricular structure and filling in mild-to-moderate hypertension | |
| Stewart et al. | The Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Patients with HEpEF | |
| Perchet et al. | Post-exercise Doppler-echocardiographic haemodynamics in idiopathic dilated cardiomyopathy after metoprolol infusion | |
| Brassard | Impact of type 2 diabetes on cardiorespiratory function and exercise performance | |
| Stott et al. | Ischaemic heart disease in elderly patients | |
| Energy | Exercise Physiology | |
| Begley | Modifying Factors in the Phenotypic Expression of Hypertrophic Cardiomyopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140226 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140305 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140314 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140324 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20140603 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150401 |